Abstract Library

#4497 Complex management of a long-term gastrinoma survivor with multimodal treatment approaches

Introduction: The prognosis of pancreatic gastrinomas is influenced by tumour burden, extent of metastasis, and treatment response, with 5-year survival rates ranging from 20% to 40%. Treatment for well-differentiated tumours typically include locoregional therapies, long-acting somatostatin analogues, molecular targeted agents, radionuclides, and chemotherapy.

Conference:

Presenting Author: Puscasu A

Authors: Puscasu A, Miron M, Croitoru A,

Keywords: gastrinoma, neuroendocrine tumour, long survival, complex management,

#4292 Predictors based on the radiologic characteristics for aggressiveness of small (＜20 mm) non-functioning pancreatic neuroendocrine tumours

Introduction: The management of small non-functioning PNETs remains controversial due to their heterogeneity. Results from some retrospective surgical reports found that a subset of small NF-PNETs may show aggressive behaviour, for which surgical resection is recommended.

Conference:

Presenting Author: Shu-Jie R

Authors: Ren S, Fan Y, Tan C, Wang X, Tan Q,

Keywords: small pancreatic neuroendocrine tumour, high-risk factor, radiologic characteristics, tumour marker, prognostic factor,

#2833 Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels

Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Shah H

Authors: Shah H, Sagar V, Venkataraman H, Steeds R, Rooney S,

Keywords: carcinoid, carcinoid syndrome, neuroendocrine tumour, carcinoid heart disease, 5hiaa,

#1233 CA 19-9: A Novel Role in the Prognosis of Pancreatic Neuroendocrine Tumors

Introduction: Prognostication is difficult for neuroendocrine tumours given their long survival. Staging, grading using Ki67 and receptor status are tools commonly used, but are not without their limitations. CA 19-9 is a tumour marker used in the diagnosis and follow-up of pancreatic adenocarcinomas despite multiple confounding factors, including jaundice. CA 19-9 is not useful in the diagnosis of PNETs having a sensitivity of only 19%, but it is not known whether it has other roles in PNETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Mills L, Ramage J, Quaglia A, Basuroy R, Srirajaskanthan R,

Keywords: CA 19-9,

#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust

Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Teo L, Hearn K, Bernstone G, Wright R, Manus D,

Keywords: CgA, 5-HIAA, octreotide, lanreotide, prognosis, staging, neuroendocrine tumors,